These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38953697)

  • 21. Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants.
    Elhusein AM; Fadlalmola HA; Abedelwahed HH; Elshaikh AA; Banaga AE; Alrahman MHF; Abdelgadim NH; Mohammed IH; Abdalla AAA; Abdalla FAM; Abd Allah EM; Abbas NI; Alhujaili AD; Almkiy EA; Idress EA; Awadalkareem EM; Abdeldafie SY; Balusamy P; Mohamed RA; Aloufi RSM; Habiballa M; Abdelmalik MA; Alhejaili MM; Ibrahim IA; Masaad HK
    Afr J Reprod Health; 2024 Mar; 28(3):99-113. PubMed ID: 38583073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
    Akhtar SMM; Ali A; Khan MS; Khan V; Fareed A; Saleem SZ; Mumtaz M; Ahsan MN; Iqbal S; Asghar MS
    Int J Gynaecol Obstet; 2024 Apr; ():. PubMed ID: 38563867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.
    Rani P; Zehra D; Mansoor M; Rani P
    Arch Womens Ment Health; 2024 Mar; ():. PubMed ID: 38478035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis.
    Shan D; Zou L; Liu X; Shen Y; Cai Y; Zhang J
    Am J Obstet Gynecol; 2020 Jun; 222(6):564-579.e12. PubMed ID: 31870736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
    Santoro N; Nappi RE; Neal-Perry G; English M; King DD; Yamaguchi Y; Ottery FD
    Menopause; 2024 Apr; 31(4):247-257. PubMed ID: 38517210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause.
    Shapiro C M M; Cano A; Nappi RE; Santoro N; English ML; Mancuso S; Morga A; Siddiqui E; Valluri U; Ottery FD
    Maturitas; 2024 Aug; 186():107999. PubMed ID: 38749864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fezolinetant: First Approval.
    Lee A
    Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment.
    Rapkin AJ
    Am J Obstet Gynecol; 2007 Feb; 196(2):97-106. PubMed ID: 17306645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
    Nappi RE; Johnson KA; Stute P; Blogg M; English M; Morga A; Scrine L; Siddiqui E; Ottery FD
    Menopause; 2024 Jun; 31(6):512-521. PubMed ID: 38626380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data.
    Morga A; Zimmermann L; Valluri U; Siddiqui E; McLeod L; Bender RH
    Adv Ther; 2024 Jul; 41(7):2845-2858. PubMed ID: 38775925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.
    Carris N; Kutner S; Reilly-Rogers S
    Ann Pharmacother; 2014 Oct; 48(10):1343-9. PubMed ID: 25028744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review.
    Utian WH
    Health Qual Life Outcomes; 2005 Aug; 3():47. PubMed ID: 16083502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal.
    Gompel A; Stuenkel CA
    Cell Rep Med; 2023 Jun; 4(6):101076. PubMed ID: 37343519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy.
    Hassan F; Saleem A; Samuel SS; Sarfraz Z; Sarfraz A; Sarfraz M; Kc M
    Medicine (Baltimore); 2023 Jun; 102(23):e33978. PubMed ID: 37335635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of desvenlafaxine succinate for menopausal hot flashes.
    Tella SH; Gallagher JC
    Expert Opin Pharmacother; 2014 Nov; 15(16):2407-18. PubMed ID: 25252697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of purified pollen extract for reducing vasomotor symptoms in women: a systematic review and meta-analysis.
    Acquarulo EL; Hernandez EC; Kodzodziku F; Nemec EC
    Menopause; 2024 Feb; 31(2):154-159. PubMed ID: 38194609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause.
    Fugate SE; Church CO
    Ann Pharmacother; 2004 Sep; 38(9):1482-99. PubMed ID: 15292498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
    Neal-Perry G; Cano A; Lederman S; Nappi RE; Santoro N; Wolfman W; English M; Franklin C; Valluri U; Ottery FD
    Obstet Gynecol; 2023 Apr; 141(4):737-747. PubMed ID: 36897180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormonal and nonhormonal treatment of vasomotor symptoms.
    Krause MS; Nakajima ST
    Obstet Gynecol Clin North Am; 2015 Mar; 42(1):163-79. PubMed ID: 25681847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2004; 11(1):11-33. PubMed ID: 14716179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.